Cargando…
JAK inhibitors and the risk of malignancy: a meta-analysis across disease indications
OBJECTIVES: To estimate the association of Janus kinase inhibitors (JAKi) with the incidence of malignancy, compared with placebo, tumour necrosis factor (TNF)-α inhibitors (TNFi) and methotrexate. METHODS: Systematic searches of databases were performed, to December 2022, to identify phase II/III/I...
Autores principales: | Russell, Mark D, Stovin, Christopher, Alveyn, Edward, Adeyemi, Olukemi, Chan, Chun Kit David, Patel, Vishit, Adas, Maryam A, Atzeni, Fabiola, Ng, Kenrick K H, Rutherford, Andrew I, Norton, Sam, Cope, Andrew P, Galloway, James B |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BMJ Publishing Group
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10359573/ https://www.ncbi.nlm.nih.gov/pubmed/37247942 http://dx.doi.org/10.1136/ard-2023-224049 |
Ejemplares similares
-
The infection risks of JAK inhibition
por: Adas, Maryam A., et al.
Publicado: (2021) -
A Systematic Review and Meta-Analysis of Anti-Rheumatic Drugs and Pneumococcal Vaccine Immunogenicity in Inflammatory Arthritis
por: Nagra, Deepak, et al.
Publicado: (2023) -
Waiting for JAK inhibitor safety data
por: Kragstrup, Tue Wenzel, et al.
Publicado: (2022) -
JAK inhibitors disrupt T cell-induced proinflammatory macrophage activation
por: Nyirenda, Mukanthu H, et al.
Publicado: (2023) -
RMD commentary, JAK kinase inhibitors: a preferred alternative to TNF inhibitors?
por: Strand, Vibeke
Publicado: (2021)